Pomahope 3mg capsules | Pomalidomide |Millionpharma
POMAHOPE 3MG
 |
IMMUNE MODULATORY |
DESCRIPTION
Pomalidomide is sold under the brand name Pomahope 3mg and it belongs to anti-neoplastic drugs
Pomahope 3mg is doable as orally bioavailable thalidomide derivative associated with numerous therapeutic activities such as: immune modulatory, anti-angiogenesis, anti-neoplastic.
Pomahope 3mg combination with dexamethasone will cause liver injury
The primary indication of Pomahope 3mg is used in the treatment of Multiple Myeloma condition.
In this condition, Pomahope 3mg is used by combining with dexamethasone.
Pomahope 3mg capsules are applicable in;
Previously the Patients treated with two treatment such as proteasome inhibitor & Lenalidomide.
Patients who are suffered with disease progression condition
Pomahope 3mg treatment should be followed within 60 days in patients who are concluded the last treatment.
MECHANISM OF ACTION
Pomahope 3mg capsules has three primary pharmacological activities against cancer cells.
Pomalidomide includes in the way cancer proliferation and provoke the apoptosis of cancer cells.
Pomalidomide enhance the T cell & natural killer cells interceding immunity & inhibits the formation of pro inflammatory cytokines from monocytes.
Pomalidomide forbid the new cell formation. The binding of Pomalidomide to active site of targeted cell causes inhibition of ubiquitin ligase action.
Ingredients : Pomalidomide
Strength : 3mg
Manufactured : Abbott
Package : 21 capsules
PHARMACOKINETICS
The time to high serum concentration of Pomalidomide is reaches between 2 to 3 hours.
It should be administered with or without food. Hence No effect of food should be produced;
Volume of distribution of Pomalidomide is between 62 & 138L in steady state.
The Pomalidomide distribution by 67% of serum level at after 4 hours of drug intake.
human plasma protein by bounding range of 12% & 44%.
Hepatically mediated through CYP1A2, CYP3A4 is Pomalidomide is metabolized.
Pomalidomide clearance value is 7 to 10L/hr.
Doses are excreted via urine 73% & feces 15% respectively.
Doses are excreted as an unchanged form via urine 2% & feces 8%.
Pomalidomide half-life period is 9.5 hours.
During multiple myeloma malignancies;
The dosage recommendation of Pomahope 3mg is 4mg should be administered as a single dose for 1 to 21 days of successive 28-day cycles.
Pomahope is combined with dexamethasone with low dose.
Administrate Dexamethasone on day 1, 8, 15 & 22 of each 28-day cycle.
The prescribed dose of dexamethasone is 40mg should be administered the patient having weight about ≤ 75kg.
The prescribed dose of dexamethasone is 20mg given for patient’s weight Greater than 75kg
Dosage alteration during hematological toxicities;
Neutropenia;
ANC <500/mcL: Pomahope treatment should be postponed and check the CBC weekly.
ANC ≥ 500/mcL: Pomahope therapy should be continued by 3mg/day
For each successive drop <500/mcL: Pomahope 3mg should be postponed.
ANC ≥ 500/mcL: Continue the Pomahope therapy with 1mg/day.
Thrombocytopenia;
Platelets count <25000/mcL: Pomahope therapy should be postponed and check CBC
Platelets count ≥50000/mcL: 3mg of Pomahope should be taken daily
With strong CYP1A2;
Pomahope combined with CYP1A2 substrates causes increasing the plasma concentration of Pomalidomide and leads to elevate the risk of Pomalidomide. In renal damaged patients;
In severe renal impaired patients, the suggested dose of Pomahope is 3mg per day.
In hepatic impaired patients;
The advised dose is 3mg/day & in severe condition, the suggested dose is 2mg/day given for mild to moderate patients.
CONTACT US
MOBILE NO : +91-9940472902EMAIL : millionhealthpharmaceuticals@gmail.com
WEBSITE URL : https://millionpharma.com/pomahope-3mg.php
Comments
Post a Comment